請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78848
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊家榮 | |
dc.contributor.author | Fang-I Huang | en |
dc.contributor.author | 黃芳儀 | zh_TW |
dc.date.accessioned | 2021-07-11T15:23:50Z | - |
dc.date.available | 2024-03-11 | |
dc.date.copyright | 2019-03-11 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-01-25 | |
dc.identifier.citation | 參考文獻
1. Duvic M, et al. Histone deacetylase inhibitors: SAHA (Vorinostat). A treatment option for advanced cutaneous T-cell lymphoma. Blood. 2007;109:31-9. 2. Ververis K, Rodd AL, Tang MM, El-Osta A, Karagiannis TC. Histone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytes. Cell Mol Life Sci. 2011;68:4101-14. 3. Zhang Y, et al. Mice lacking histone deacetylase 6 have hyperacetylated tubulin but are viable and develop normally. Mol Cell Biol. 2008;28:1688-701. 4. Santo L, et al. Preclinical activity, pharmacodynamics, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 2012;119:2579-89. 5. The website of ClinicalTrials.gov. http://www.clinicaltrials.gov/ 6. Hideshima T, et al. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7:585-98. 7. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2018. CA Cancer J Clin. 2018; 68:7-30. 8. CANCER REGISTRY ANNUAL REPORT, 2015 TAIWAN 9. Landgren O, Rajkumar SV. New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple Myeloma. Clin Cancer Res. 2016;22:5428-33. 10. Kumar SK, et al. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. J Natl Compr Canc Netw. 2018;16:11-20. 11. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1:194-202. 12. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett. 2009;277:8-21 13. Piekarz R, Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des. 2004;10:2289-98. 14. Richardson PG, Harvey RD, Laubach JP, Moreau P, Lonial S, San-Miguel JF. Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes. Expert Rev Clin Pharmacol. 2016;9:35-48. 15. Srinivas NR. Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: Review and perspectives. Xenobiotica 2017;47:354-68. 16. Marks PA, Xu WS. Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem. 2009;107:600-8. 17. Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, et al. Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 2013;14:1129-40. 18. Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone Deacetylase Inhibitors as Anticancer Drugs. Int J Mol Sci. 2017;18:pii: E1414. 19. Batchu SN, Brijmohan AS, Advani A. The therapeutic hope for HDAC6 inhibitors in malignancy and chronic disease. Clin Sci. 2016;130:987-1003. 20. Boyault C, et al. HDAC6-p97/VCP controlled polyubiquitin chain turnover. EMBO J. 2006;25:3357-66. 21. Hook SS, Orian A, Cowley SM, Eisenman RN. Histone deacetylase 6 binds polyubiquitinthrough its zinc finger (PAZ domain) and copurifieswith deubiquitinating enzymes. Proc Natl Acad Sci USA. 2009;99:13425-30. 22. Seigneurin-Berny D, et al. Identification of components of the murine histonedeacetylase 6 complex: link between acetylation and ubiquitination signaling pathways. Mol Cell Biol. 2001;21:8035-44. 23. Yan J. Interplay between HDAC6 and its interacting partners: essential roles in the aggresome-autophagy pathway and neurodegenerative diseases. DNA Cell Biol. 2014;33:567-80. 24. Li T, Zhang C, Hassan S, Liu X, Song F, Chen K. Histone deacetylase 6 in cancer. J Hematol Oncol. 2018;11:111-8. 25. Majid T, Griffin D, Criss Z 2nd, Jarpe M, Pautler RG. Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice. Alzheimers Dement (N Y). 2015 11;1:170-81. 26. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4:349-60. 27. Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther. 2011;10:2034-42. 28. Lichter DI, et al. Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood. 2012;120:4513-6. 29. Bennett EJ, Bence NF, Jayakumar R, Kopito RR. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol Cell. 2005;17:351-65. 30. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood. 1999;93:1658-67. 31. Alzheimer’s, A. Alzheimer’s disease facts and figures. Alzheimers Dement. 2018; 14: 367-429. 32. Lane CA, Hardy J, Schott JM. Alzheimer's disease. Eur J Neurol. 2018;25:59-70. 33. Golde TE, Petrucelli L, Lewis J. Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol. 2010;223:252-66. 34. Murphy MP, LeVine H. Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis. 2010;19:311-23. 35. Cheignon C, Tomas M, Bonnefont-Rousselot D, Faller P, Hureau C, Collin F. Oxidative stress and the amyloid beta peptide in Alzheimer's disease. Redox Biol. 2018;14:450-64. 36. Iqbal K, et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta. 2005;1739:198-210. 37. Martin L, Latypova X, Wilson CM, Magnaudeix A, Perrin ML, Yardin C, et al. Tau protein kinases: involvement in Alzheimer's disease. Ageing Res Rev. 2013;12:289-309. 38. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002;103:26-35. 39. Martin L, Page G, Terro F. Tau phosphorylation and neuronal apoptosis induced by the blockade of PP2A preferentially involve GSK3β. Neurochem Int. 2011;59: 235-50. 40. Hernández F, Gómez de Barreda E, Fuster-Matanzo A, Lucas JJ, Avila J. GSK3: a possible link between beta amyloid peptide and tau protein. Exp Neurol. 2010;223:322-5. 41. Lee JK, Kim NJ. Recent Advances in the Inhibition of p38 MAPK as a Potential Strategy for the Treatment of Alzheimer's Disease. Molecules. 2017;22:pii: E1287. 42. Munoz L, Ammit AJ. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology. 2010;58:561-8. 43. Zhu X, Lee HG, Raina AK, Perry G, Smith MA. The role of mitogen-activated protein kinase pathways in Alzheimer's disease. Neurosignals. 2002;11:270-81. 44. Engmann O, Giese KP. Crosstalk between Cdk5 and GSK3beta: Implications for Alzheimer's Disease. Front Mol Neurosci. 2009;2:2. 45. Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci. 2016;17:5-21. 46. Castro-Alvarez JF, Uribe-Arias SA, Mejía-Raigosa D, Cardona-Gómez GP. Cyclin-dependent kinase 5, a node protein in diminished tauopathy: a systems biology approach. Front Aging Neurosci. 2014;6:232. 47. Šimić G, et al. Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies. Biomolecules. 2016;6:6. 48. Sulistio YA, Heese K. The ubiquitin-proteasome system and molecular chaperone deregulation in Alzheimer’s disease. Mol Neurobiol. 2016;53;905-31. 49. Cook, C. et al. Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation. Hum. Mol Genet. 2012;21;2936-45. 50. Scroggins BT, et al. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol Cell. 2007;25:151-9. 51. Bali P, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90. J Biol Chem. 2005;280:26729-34. 52. Nimmanapalli R, et al. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res. 2003;63:5126-35. 53. Lei P, Ayton S, Bush AI, Adlard PA. GSK-3 in neurodegenerative disease. Int J Alzheimers Dis. 2011;2011;189246. 54. Lee MS, Tsai LH Cdk5: one of the links between senile plaques and neurofibrillary tangles? J Alzheimers Dis. 2003;5:127-37. 55. Wang Y, et al. Cross talk between PI3K-AKT-GSK-3β and PP2A pathways determines tau hyperphosphorylation. Neurobiol Aging. 2015;36:188-200. 56. Leroy K, Yilmaz Z, Brion JP. Increased level of active GSK-3β in Alzheimer’s disease and accumulation in argyrophilic grains and in neurons at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol. 2007;33:43-55. 57. Engel T, et al. Cooexpression of FTDP-17 tau and GSK-3β in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol Aging. 2006;27:1258-68. 58. Hernández F, Gómez de Barreda E, Fuster-Matanzo A, Lucas JJ, Avila J. GSK3: a possible link between beta amyloid peptide and tau protein. Exp Neurol. 2010;223:322-5. 59. Takashima A, et al. Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3β. Neurosci Lett. 1996;203:33-6. 60. Chen CC, Chow MP, Huang WC, Lin YC, Chang YJ. Flavonoids inhibit tumor necrosis factor-alpha-induced up-regulation of intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells through activator protein-1 and nuclear factor-kappaB: structure-activity relationships. Mol Pharmacol. 2004;66:683-93. 61. Götz J, Ittner LM. Animal models of Alzheimer's disease and frontotemporal dementia. Nat Rev Neurosci. 2008;9:532-44. 62. Lee HY, et al. 5-Aroylindoles act as selective histone deacetylase 6 inhibitors ameliorating Alzheimer's disease phenotypes. J Med Chem. 2018;61:7087-102. 63. Duvic M. Histone deacetylase inhibitors: SAHA (Vorinostat). A treatment option for advanced cutaneous T-cell lymphoma. Hematol Meet Rep. 2008;2:39-43. 64. Ververis K, Rodd AL, Tang MM, El-Osta A, Karagiannis TC. Histone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytes. Cell Mol Life Sci. 2011;68:4101-14. 65. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7:585-98. 66. Mishima Y, et al. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death. Br J Haematol. 2015;169:423-34. 67. Bennett EJ, Bence NF, Jayakumar R, Kopito RR. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol Cell. 2005;17:351-65. 68. Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell. 2003;115:727-38. 69. Bett JS. Proteostasis regulation by the ubiquitin system. Essays Biochem. 2016;60:143-51. 70. Hideshima T, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci USA. 2005;102:8567-72. 71. Wang J, et al. Bone marrow stromal cell–derived exosomes as communicators in drug resistance in multiple myeloma cells. Blood. 2014;124:555-66. 72. Ding N, Ping L, Feng L, Zheng X, Song Y, Zhu, J. Histone deacetylase 6 activity is critical for the metastasis of Burkitt’s lymphoma cells. Cancer Cell Int. 2014;14:139. 73. Mahlknecht U, Schönbein C. Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells. Hematologica. 2008;93:443-6. 74. Noborio-Hatano K, et al. Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene. 2009;28:231-42. 75. Huang YC, Huang FI, Mehndiratta S, Lai SC, Liou JP, Yang CR. Anticancer activity of MPT0G157, a derivative of indolylbenzenesulfonamide, inhibits tumor growth and angiogenesis. Oncotarget. 2015;6:18590-601. 76. Young-Pearse TL, et al. A critical function for beta-amyloid precursor protein in neuronal migration revealed by in utero RNA interference. J. Neurosci. 2007;27: 14459-69. 77. Hoover BR, et al. Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron. 2010;68:1067-81. 78. Anand R, Gill KD, Mahdi AA. Therapeutics of Alzheimer's disease: past. Neuropharmacology. 2014;76:27-50. 79. Govindarajan N, et al. Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer’s disease. EMBO Mol Med. 2013;5:52-63. 80. Simic G, et al. Tau protein hyperphosphorylation and aggregation in Alzheimer’s disease and other tauopathies, and possible neuroprotective strategies. Biomolecules. 2016;6:6. 81. Dou F, et al. Chaperones increase association of tau protein with microtubules. Proc Natl Acad Sci USA. 2003;100:721-6. 82. Kovacs JJ, et al. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell. 2005;18:601-7. 83. Lei P, Ayton S, Bush AI, Adlard PA. GSK-3 in neurodegenerative disease. Int J Alzheimers Dis. 2011;2011:189246. 84. The web site of Alzforum networking for cure. https://www.alzforum.org/research-models/3xtg 85. Lee MS, Tsai LH. Cdk5: one of the links between senile plaques and neurofibrillary tangles? J Alzheimers Dis. 2003;5:127-37. 86. Ding H, Dolan PJ, Johnson GV. Histone deacetylase 6 interacts with the microtubule-associated protein tau. J Neurochem. 2008;106:2119-30 . 87. Govindarajan N, et al. Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer’s disease. EMBO Mol Med. 2013;5:52-63. 88. Anandatheerthacarada HK, Biswas G, Robin MA, Avadhani NG. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer’s amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol. 2003;161: 41-54. 89. Lin N, et al. Tripchlorolide attenuates β-amyloid generation via suppressing PPARγ-regulated BACE1 activity in N2a/APP695 cells. Mol Neurobiol. 2016;53:6397-406. 90. Wang YP, et al. Endogenous overproduction of beta-amyloid induces tau hyperphosphorylation and decreases the solubility of tau in N2a cells. J Neural Transm. (Vienna) 2006;113:1723-32. 91. Liu JD, et al. Efficacy and Safety of Panobinostat in Relapsed or/and Refractory Multiple Myeloma: Meta Analyses of Clinical Trials and Systematic Review. Sci Rep. 2016;6:27361. 92. Zhang L, et al. Tubastatin A/ACY-1215 improves cognition in Alzheimer's disease transgenic mice. J Alzheimers Dis. 2014;41:1193-205. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/78848 | - |
dc.description.abstract | 多發性骨髓瘤(multiple myeloma, MM)是B細胞惡性腫瘤,好發於年長者(65歲以上),在台灣,每年估計有500名病患確診為多發性骨髓瘤。阿茲海默症(Alzheimer’s disease, AD),為最主要造成失智症的原因之一,約有60-80%失智患者同時患有阿茲海默症,在台灣約每100人就有一人為失智症。以上二者疾病都經過多年的研究,但至今我們仍在尋找更好的治療策略,然而台灣已於2018年3月正式邁向高齡化社會,預計將會有越來越多人遭受這樣的疾病,因此急需尋求更好的解決方法。
組蛋白乙醯化(Histone acetyltransferase, HAT)和脫乙醯化 (Histone deacetylae, HDAC)是調節基因表達和轉錄的重要表現的遺傳機制。組蛋白去乙醯化酶6(Histone deacetylae, HDAC6)是HDAC家族的獨特成員,不僅參與組蛋白乙醯化和脫乙醯化,而且還靶向幾種非組蛋白基質,如α-tubulin,cortactin和熱休克蛋白90(Hsp90),以調節腫瘤細胞增殖,轉移,侵襲和有絲分裂。另外研究發現HDAC6 konckout小鼠沒有器官損傷。可見HDAC6是治療疾病的新靶點。在本論文中,我們研究了HDAC6抑制劑在調節MM生長和AD中神經保護中的作用。 在第三章,我們發現HDAC6抑制劑與bortezomib(BTZ)的組合可以增加ubiquitinated protein的積累,然後引起進一步的細胞凋亡。HDAC6合併BTZ可以阻斷蛋白酶體和聚集體(aggresome)路逕是錯誤折疊蛋白清除的兩個主要途徑,同時維持MM穩定生長。HDAC6在聚集體途徑中有重要作用,因為它可以結合ployubiquitinated protein的蛋白質和動力蛋白馬達(dynein),然後將這種蛋白質轉運到聚集體中以進一步降解。此外,我們發現合併治療還可以抑制MM黏著於骨髓基質細胞(BMSC),降低MM-BMSC共培養體系中vascular endothelial growth factor (VEGF),Interleukin 6 (IL-6)的表現量以及MM生長,表示聯合治療擾亂骨髓微環境。此外,在異種移植SCID小鼠模行中MPT0G413-BTZ組合治療組中腫瘤生長顯著降低。我們的研究表明,合併治療具有協同抑制MM活性,為合併治療的臨床評估提供方法,以改善患者多發性骨髓瘤的癒後。 在第四章,我們使用AD模型研究HDAC6抑制劑的作用和機制。我們發現有兩種減少tau蛋白磷酸化和聚集的途徑與neurofibrillary tangle (NFT)的形成相關。一種是HDAC6抑制活性導致乙醯化Hsp90的增加,其反過來降低Hsp90和HDAC6的結合,並且磷酸化tau被轉移至Hsp90複合物,然後導致磷酸化tau蛋白的泛素化。另一種是通過Akt磷酸化顯著增加無活性形式的phospho-glycogen synthase kinase-3β (phospho-GSK3β)以減少tau磷酸化。基於這一發現,我們發現HDAC6抑制劑具有改善AD表徵的能力,包括tau蛋白過度磷酸化和聚集,神經保護作用以及學習和記憶缺陷的改善,使其成為進一步發展AD治療的潛力藥物。 | zh_TW |
dc.description.abstract | Multiple myeloma (MM) is a B cell malignancy. In Taiwan, There an estimated 500 patients diagnosed with multiple myeloma each year. Alzheimer's disease (AD) is one of the most common causes of dementia. About 60-80% of patients with dementia suffer from Alzheimer's disease. That means one in every 100 people in Taiwan is dementia. However, Taiwan has been an aging society. It is expected that more and more people will suffer from such diseases, so it is urgent to seek better solution.
Histone acetylation and deacetylation are important epigenetic mechanisms that regulate gene expression and transcription. Histone deacetylase 6 (HDAC6) is a unique member of the HDAC family that not only participates in histone acetylation and deacetylation but also targets several nonhistone substrates, such as α-tubulin, cortactin, and heat shock protein 90 (Hsp90), to regulate cell proliferation, metastasis, invasion, and mitosis in tumors. There is no organ damage in HDAC6 konckout mice. HDAC6 is a new target to cure the disease. In this thesis, we investigated the function of HDAC6 inhibitors in regulating multiple myeloma growth and neuroprotecting in AD. In the third chapter, we report the combination HDAC6 inhibitors with bortezomib (BTZ) can increase the accumulation of ubiquitinated proteins then cause further apoptosis. HDAC6 combined with bortezomib could block proteasomal and aggresomal pathways, two major pathways for misfolded protein clearance to maintain MM homeostasis at the same time. HDAC6 plays an important role in aggresomal pathway since it can bind polyubiquitinated proteins and dynein motors, then transport this protein cargo to aggresome for further degradation. Moreover, we found that the combination therapy can also inhibit MM adherence to bone marrow stromal cells (BMSC) and decreas VEGF, IL-6 levels and MM growth in MM-BMSC co-culture system, suggest combination treatment disturbed bone marrow microenvironment. In addition, tumor growth was significantly reduced in MPT0G413-BTZ combination treatment group in xenograft SCID mouse model. Our studies demonstrate that the combination therapy exhibits synergic anti-MM viability, providing the framework for clinical evaluation of combined therapy to improve patient’s outcome in multiple myeloma. In the forth chapter, we investigate the effects and mechanism of the HDAC6 inhibitor by using an AD model. We found that there are two pathway of decreasing tau protein phosphorylation and aggregation correlated with the formation of NFTs. One is HDAC6 inhibitory activity led to the increase of acetylated Hsp90, which in turn decreased the binding of Hsp90 and HDAC6, and phosphorylated tau was transferred to the Hsp90 complex then leading to the ubiquitination of phosphorylate tau proteins. The other one is a significant increased the inactive form phospho-glycogen synthase kinase-3β (phospho-GSK3β) through Akt phosphorylation to reduce the tau phosphorylation. Base on this findings, we found that the ability of HDAC6 inhibitors to improve Alzheimer’s disease phenotypes including tau hyperphosphorylation and aggregation, neuroprotective effects upon ubiquitination, and amelioration of learning and memory deficits, makes it a potential agent for further development as a treatment for Alzheimer’s disease. | en |
dc.description.provenance | Made available in DSpace on 2021-07-11T15:23:50Z (GMT). No. of bitstreams: 1 ntu-108-D01423203-1.pdf: 23013067 bytes, checksum: 9d9d29e413288bfab5559c3c4de08f73 (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 目錄
縮寫表…………………………………………………………………...III 中文摘要………………………………………………………………...VI 英文摘要………………………………………………………………VIII 第一章 第一節研究動機與目的…………………………………………1 第二節文獻回顧…………………………………………………3 第二章實驗材料與方法………………………………………………...26 第三章HDAC6抑制劑與Bortezomib合併使用對多發性骨髓瘤的生長有協同性的抑制作用……….....………………………………...38 第一節中文摘要……………………………………………..….39 第二節英文摘要………………………………………………...40 第三節實驗結果………………………………………………...41 第四節實驗討論………………………………………………...45 第四章HDAC6抑制劑可以改善阿茲海默症動物模型中tau蛋白聚集以及認知記憶…………………………………………………...66 第一節中文摘要………………………………………………...67 第二節英文摘要………………………………………………...68 第三節實驗結果………………………………………………...70 第四節實驗討論………………………………………………...74 第五章結論與未來展望………………………………………………...89 參考文獻………………………………………………………………...91 | |
dc.language.iso | zh-TW | |
dc.title | 新型HDAC6選擇性抑制劑之抗多發性骨髓瘤與阿茲海默症活性與機轉探討 | zh_TW |
dc.title | Effects and action mechanisms of novel HDAC6 inhibitor in multiple myeloma and Alzheimer’s disease | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-1 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 潘秀玲,劉景平,許麗卿,顧記華,孔繁璐 | |
dc.subject.keyword | 多發性骨髓瘤細胞,組蛋白去乙醯化?6,bortezomib,合併治療,骨髓基質細胞,協同作用, | zh_TW |
dc.subject.keyword | Multiple myeloma cells,histone deacetylase 6,bortezomib,combination therapy,bone marrow stromal cells,synergistic effect, | en |
dc.relation.page | 101 | |
dc.identifier.doi | 10.6342/NTU201900205 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2019-01-28 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
dc.date.embargo-lift | 2024-03-11 | - |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-D01423203-1.pdf 目前未授權公開取用 | 22.47 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。